WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018089786) ATG7 INHIBITORS AND THE USES THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/089786    International Application No.:    PCT/US2017/061094
Publication Date: 17.05.2018 International Filing Date: 10.11.2017
IPC:
C07D 487/04 (2006.01), A61K 31/519 (2006.01)
Applicants: MILLENNIUM PHARMACEUTICALS, INC. [US/US]; 40 Landsdowne Street Cambridge, MA 02139 (US)
Inventors: ADHIKARI, Sharmila; (US).
CALDERWOOD, Emily, Frances; (US).
ENGLAND, Dylan, Bradley; (US).
GOULD, Alexandra, E.; (US).
HARRISON, Sean, J.; (US).
HUANG, Shih-Chung; (US).
MA, Liting; (US)
Agent: CHANGGANG, Lou; (US).
CLOUTIER, Mario; (US).
HORWITZ, Lillian; (US).
SIOUSSAT, Tracy, M.; (US).
YEUNG, Constance; (US)
Priority Data:
62/420,630 11.11.2016 US
Title (EN) ATG7 INHIBITORS AND THE USES THEREOF
(FR) INHIBITEURS D'ATG7 ET LEURS UTILISATIONS
Abstract: front page image
(EN)Disclosed are chemical entities which are compounds of formula (I) : or a pharmaceutically acceptable salt thereof, wherein R1, R2, and Ra have the values described herein. Chemical entities according to the disclosure can be useful as inhibitors of ATG7. Further provided are pharmaceutical compositions comprising a chemical entity of the disclosure and methods of using the compositions in the treatment of cancer.
(FR)L'invention concerne des entités chimiques qui sont des composés de formule (I) : ou un sel pharmaceutiquement acceptable de ceux-ci, où R1, R2, et Ra ont les valeurs décrites ici. Les entités chimiques selon l'invention peuvent être utiles en tant qu'inhibiteurs d'ATG7. L'invention concerne en outre des compositions pharmaceutiques comprenant une entité chimique de l'invention et des méthodes d'utilisation des compositions dans le traitement du cancer.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)